Eliem Therapeutics

Redmond, WA, US

Eliem Therapeutics develops drug candidates for nervous system disorders, including chronic pain, mood disorders and epilepsy. It aims to provide new treatment options for people affected by these conditions.

Facts

HQ
Redmond, WA, US
Sectors
Biotech, Pharmaceuticals, Healthcare
Stage
Public
Members see funding amounts.
.

Is this your organization? Claim it

Eliem Therapeutics raises $80M in IPO, prices 6.4M shares at $12.50 and lists on Nasdaq as ELYM

Eliem Therapeutics priced 6.4 million shares at $12.50 in an IPO that raised $80 million and will trade on Nasdaq as ELYM, with shares closing at $15.90 (up 27%). The Redmond biotech, founded ~3 years ago and led by Bob Azelby, is early-stage with no product revenue, a $46.7M deficit, 25 employees, and is developing CNS-focused therapies for pain, psychiatry and epilepsy.

See all 6 stories, episodes and videos about Eliem Therapeutics.